How do trial teams plan for retention during the design stage of the trial? A scoping review protocol
DiscussionThe scoping review will help trial methodologists better understand if retention strategies are planned for during the design stage of the trial contributing to the PRioRiTy II unanswered question “How should people who run trials plan for retention during their funding application and creation of the trial (protocol development)?”. (Source: Trials)
Source: Trials - November 17, 2022 Category: Research Source Type: clinical trials
NIH Seeks the Next Generation of COVID-19 Diagnostics
September 8, 2022 -- The National Institutes of Health has issued two new funding opportunities for diagnostic test manufacturers to develop the next generation of COVID-19 tests, with a major focus on accessibility. The funding opportunities are... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 8, 2022 Category: Pharmaceuticals Source Type: clinical trials
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units
We report and give guidance on operational aspects which are either harder to implement compared to a traditional late-phase trial or are specific to platform protocols.ResultsWe present a list of practical recommendations for trialists intending to design and conduct late-phase platform protocols. Our recommendations cover the entire life cycle of a platform trial: from protocol development, obtaining funding, and trial set-up, to a wide range of operational and regulatory aspects such as staffing, oversight, data handling, and data management, to the reporting of results, with a particular focus on communication with tri...
Source: Trials - September 6, 2022 Category: Research Source Type: clinical trials
SWITCH ON: Analysing the Immunogenicity of Additional Booster Vaccinations in HCW
Condition: Covid-19 Vaccination Interventions: Drug: Direct boost mRNA; Drug: Direct boost adeno; Drug: Post-poned boost mRNA; Drug: Post-poned boost adeno Sponsors: Erasmus Medical Center; ZonMw (Funding organisation, The Hague, The Netherlands); LUMC, University Hospital (Leiden, The Netherlands); UMCG, University Hospital (Groningen, The Netherlands); AUMC, University Hospital (Amsterdam, The Netherlands) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 22, 2022 Category: Research Source Type: clinical trials
